首页> Blood advances> Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL.

Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL.

导出 LinkOut

翻译打印收藏纠错

第一作者： Yaqi,Zhao

第一单位： Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN.

作者： Yaqi,Zhao ^[1] ; A Douglas,Laird ^[2] ; Kathryn G,Roberts ^[1] ; Rolla,Yafawi ^[3] ; Hagop,Kantarjian ^[4] ; Daniel J,DeAngelo ^[5] ; Matthias,Stelljes ^[6] ; Michaela,Liedtke ^[7] ; Wendy,Stock ^[8] ; Nicola,Gökbuget ^[9] ; Susan,O'Brien ^[10] ; Elias,Jabbour ^[4] ; Ryan D,Cassaday ^[11] ; Melanie R,Loyd ^[12] ; Scott,Olsen ^[12] ; Geoffrey,Neale ^[12] ; Xueli,Liu ^[13] ; Erik,Vandendries ^[14] ; Anjali,Advani ^[15] ; Charles G,Mullighan ^[1]

作者单位： Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN. ^[1] Translational Oncology, Late Development, Pfizer Inc, South San Francisco, CA. ^[2] Clinical Data Acquisition, Pfizer Inc, La Jolla, CA. ^[3] Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX. ^[4] Department of Medical Oncology/Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA. ^[5] Department of Medicine/Hematology and Oncology, Universitätsklinikum Münster, Münster, Germany. ^[6] Department of Hematology, Stanford Cancer Institute, Stanford, CA. ^[7] Department of Medicine, University of Chicago, Chicago, IL. ^[8] Department of Medicine II, Hematology/Oncology, Goethe Universität, Frankfurt, Germany. ^[9] Division of Hematology/Oncology, Medicine, University of California Irvine Medical Center, Orange, CA. ^[10] Division of Hematology, University of Washington School of Medicine and Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA. ^[11] Hartwell Center for Biotechnology, St. Jude Children's Research Hospital, Memphis, TN. ^[12] Biostatistics, Pfizer Inc, Groton, CT. ^[13] Global Product Development, Pfizer Inc, Cambridge, MA. ^[14] Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH. ^[15]

医学主题词人类(Humans);前体细胞淋巴母细胞白血病淋巴瘤(Precursor Cell Lymphoblastic Leukemia-Lymphoma);成年人(Adult);女(雌)性(Female);男(雄)性(Male);中年人(Middle Aged);治疗结果(Treatment Outcome);老年人(Aged);复发(Recurrence);青年人(Young Adult);抗药性, 肿瘤(Drug Resistance, Neoplasm);青少年(Adolescent)

DOI 10.1182/bloodadvances.2023012430

PMID 38607410

发布时间 2024-11-06

基金项目

R35 CA197695/CA/NCI NIH HHS/United States P30 CA021765/CA/NCI NIH HHS/United States

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Blood advances

2024年8卷12期

3226-3236页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

Blood advances

2024年8卷12期

3226-3236页

检索历史清除

Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL.

Blood advances

相似文献

同项目论文

Blood advances

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL.

Blood advances

相似文献

同项目论文

Blood advances

相关期刊

检索历史清除